Gain Therapeutics GANX 深 沪
等待开盘 10-17 09:30:00 美东时间
1.26
-0.070
-5.26%
华盛通- 最 高1.377
- 今 开1.32
- 成交量 33.82万股
- 最 低 1.255
- 昨 收 1.33
- 总市值 5499.10万
- 52周最高 4.34
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 1.255
- 委 比 16.80%
- 总股本 4364.36万
- 历史最高 17.93
- 量 比 0.67
- 振 幅 9.17%
- 历史最低 0.89
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gain Therapeutics to Attend the 2026 Maxim Growth Summit
Gain Therapeutics, Inc. will participate in the 2026 Maxim Growth Summit from October 12-14 in New York City. The company will meet with institutional investors and engage with Maxim research analysts. Gain’s lead drug candidate, rexaceract, is in a Phase 1b trial for Parkinson’s disease and has potential for Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. The company uses its Magellan™ platform to develop novel allosteric ...
10-08 11:00
Harvard Bioscience Announces Creation of Scientific Advisory Board
Harvard Bioscience, Inc. has established a Scientific Advisory Board (SAB) to guide its research, development, and new product strategies. The SAB includes five members: CEO John Duke, Dr. Ryan Conder of STEMCELL Technologies, Dr. Aaron Goldman of Harvard Medical School, Dr. Keith Olson of Ananda Devices, and Eric Richman of LabConnect and SafeHeal. This board aims to enhance the company's R&D and product innovation, leveraging expertise in drug ...
10-06 20:05
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
Gain Therapeutics highlights promising Parkinson’s Phase 1b data
An announcement from Gain Therapeutics ( ($GANX) ) is now available. On October...
10-01 21:50
Gain Therapeutics Reveals Poster Presentation At International Congress Of Parkinson’s Disease and Movement Disorders
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and...
09-30 05:54
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
Gain Therapeutics announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, detailing long-term open-label data on its GCase modulator, Rexaceract (GT-02287), for Parkinson’s disease treatment. Rexaceract, an orally administered small molecule, targets GBA1 mutations and age-related stress, restoring GCase function and reducing neurodegenerative markers. The Phase 1 study showed favorabl...
09-29 21:50
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
Gain Therapeutics, Inc. announced that its CEO, Gene Mack, will participate in the ROTH Healthcare Opportunities Conference on September 29, 2026, discussing "Frontiers in Neuroscience." The company is advancing its lead drug candidate, rexaceract, for Parkinson's disease and other conditions, using its Magellan platform to develop innovative therapies.
09-17 11:00
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
Gain Therapeutics, Inc. announced that its President and CEO, Gene Mack, will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York City on September 14-16, 2026. An on-demand company presentation will be available starting September 11, 2026, at 7:00 a.m. ET, accessible via the provided links. Gain Therapeutics is a clinical-stage biotechnology company focused on developing next-generation...
08-25 11:00
Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share from the same period last year.
08-11 19:30
